Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
kCfh2z6z0D66E4yE
Écouter
